2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2352

RORγt Expressing Foxp3⁺ Regulatory T Cells Regulates the Development of Autoimmune Arthritis in Mice
Abstract Number: 489

Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases
Abstract Number: 1913

Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases
Abstract Number: 2568

Routine Assessment of Patient Index Data (RAPID3) Provides Similar Information Compared to Ankylosing Spondylitis Specific Indices: Analyses of the DESIR French Cohort
Abstract Number: 297

S100 Proteins in Oligoarticular Juvenile Idiopathic Arthritis
Abstract Number: 2948

S100 Proteins Induce Canonical Wnt Signaling, Which Causes Increased Expression of MMPs in the Synovium
Abstract Number: 2952

S100A9 Inhibitor Paquinimod (ABR-215757) reduces Joint Destruction in Experimental Osteoarthritis and Blocks Activating Effects of S100A9 in OA Synovium
Abstract Number: 2764

S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes
Abstract Number: 1895

Sacroiliitis at Diagnosis in Children with Juvenile Spondyloarthritis
Abstract Number: 2822

Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
Abstract Number: 852

Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 949

Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study
Abstract Number: 2234

Safety and Efficacy of Liposome Intra-Articular Injection in Moderate Knee Osteoarthritis. a Prospective Randomized Double-Blinded Study
Abstract Number: 8

Safety and Efficacy of New Oral Direct Inhibitors of Thrombin and Factor Xa in Antiphospholipid Syndrome
Abstract Number: 2285

Safety and Efficacy of Rilonacept in Patients with Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].